Diaxinol - 120 CT

Diaxinol - 120 CT by Ortho Molecular Products

Diaxinol - 120 CT is a blood sugar support product formulated with a blend of natural ingredients and vitamins.* It is designed for maximum efficacy.* Diaxniol - 120 CT by Ortho Molecular Products might not only regulate healthy blood sugar levels, but also support detoxification.

Who Should Consider Diaxinol - 120 CT by Ortho Molecular Products?

Diaxinol - 120 CT by Ortho Molecular Products may support your health if you:

• you consume a lot of highly processed foods*
• you are under a lot of stress*
• you spend a lot of time daily remaining sedentary*

What May Diaxinol - 120 CT Support?

Ortho Molecular Products’ Diaxinol - 120 CT may have the following effects:

• support for normal cellular metabolism*
• detoxification*
• maintaining a healthy blood sugar level within the already normal range*

Supplements support your health but do not replace a balanced diet. Always check with your healthcare practitioner if you have doubts about a new supplement. Book a FREE product consultation to learn more about Diaxinol - 120 CT.

Recommendation:
Ortho Molecular suggests taking 2 capsules of Diaxinol per day or as recommended by your health care professional.

Serving Size: 2 Capsules
Servings Per Container: 60

Amount Per Serving:
Biotin USP 3,000 mcg
Chromium (as O-polynicotinate) 800 mcg
Alpha Lipoic Acid 400 mg
Cinnamon Bark Extract (Cinnulin®) 150 mg
Vanadyl Sulfate Hydrate 50 mg

Other Ingredients: Natural Vegetable Capsules, Microcrystalline Cellulose, Magnesium Stearate, and Silicon Dioxide.

This blood sugar support product does not contain gluten, corn, yeast, artificial colors, and flavors.

Caution: If you are pregnant or nursing, consult your physician before taking this product.

*These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

 Click here to view the Product Info Sheet

References:

1. Hamilton, M. T., Healy, G. N., Dunstan, D. W., Zderic, T. W., & Owen, N. (2008). Too little exercise and too much sitting: Inactivity physiology and the need for new recommendations on sedentary behavior. Current Cardiovascular Risk Reports, 2(4), 292-298.
2. Yang, E. J., Kerver, J. M., Park, Y. K., Kayitsinga, J., Allison, D. B., & Song, W. O. (2003). Carbohydrate intake and biomarkers of glycemic control among US adults: The Third National Health and Nutrition Examination Survey (NHANES III). The American Journal of Clinical Nutrition, 77(6), 1426-1433.
3. Shay, K. P., Moreau, R. F., Smith, E. J., Smith, A. R., & Hagen, T. M. (2009). Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential. Biochimica et Biophysica Acta (BBA) - General Subjects, 1790(10), 1149-1160.
4. Lee, W. J., Song, K.-H., Koh, E. H., Won, J. C., Kim, H. S., Park, H.-S., Kim, M.-S., Kim, S.-W., Lee, K.-U., & Park, J.-Y. (2005). α-Lipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochemical and Biophysical Research Communications, 332(3), 885-891.
5. Ruderman, N. B., Carling, D., Prentki, M., & Cacicedo, J. M. (2013). AMPK, insulin resistance, and the metabolic syndrome. The Journal of Clinical Investigation, 123(7), 2764-2772.
6. Towler, M. C., & Hardie, D. G. (2007). AMP-activated protein kinase in metabolic control and insulin signaling. Circulation Research, 100(3), 328-341.
7. Jacob, S., Ruus, P., Hermann, R., Tritschler, H., Maerker, E., Renn, W., Augustin, H., Dietze, G., & Rett, K. (1999). Oral administration of rac-α-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: A placebo-controlled pilot trial. Free Radical Biology and Medicine, 27(3), 309-314.
8. Packer, L., Witt, E. H., & Tritschler, H. J. (1995). Alpha-lipoic acid as a biological antioxidant. Free Radical Biology and Medicine, 19(2), 227-250.
9. Qin, B., Nagasaki, M., Ren, M., Bajotto, G., Oshida, Y., & Sato, Y. (2004). Cinnamon extract prevents the insulin resistance induced by a high-fructose diet. Hormone and Metabolic Research, 36(2), 119-125.
10. Sheng, X., Zhang, Y., Gong, Z., Huang, C., & Zang, Y. Q. (2008). Improved insulin resistance and lipid metabolism by cinnamon extract through activation of peroxisome proliferator-activated receptors. PPAR Research, 2008, 1-7.
11. Ziegenfuss, T. N., Hofheins, J. E., Mendel, R. W., Landis, J., & Anderson, R. A. (2006). Effects of a water-soluble cinnamon extract on body composition and features of the metabolic syndrome in pre-diabetic men and women. Journal of the International Society of Sports Nutrition, 3(1), 45.
12. Magistrelli, A., & Chezem, J. C. (2012). Effect of ground cinnamon on postprandial blood glucose concentration in normal-weight and obese adults. Journal of the Academy of Nutrition and Dietetics, 112(11), 1806-1809.
13. Doisy, R., Streeten, D., Freiberg, J., & Schneider, A. (2013). Chromium metabolism in man and biochemical effects. Trace Elements in Human Health and Disease, 2, 79-104.
14. Mertz, W. (2013). The interaction between chromium and insulin. In Nutrition, Digestion, Metabolism: Proceedings of the 28th International Congress of Physiological Sciences, Budapest, 1980 (p. 101).
15. Anderson, R. A., Cheng, N., Bryden, N. A., Polansky, M. M., Cheng, N., Chi, J., & Feng, J. (1997). Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes, 46(11), 1786-1791.
16. Morris, B., MacNeil, S., Hardisty, C., Heller, S., Burgin, C., & Gray, T. (1999). Chromium homeostasis in patients with type II (NIDDM) diabetes. Journal of Trace Elements in Medicine and Biology, 13(1), 57-61.
17. Kim, K.-H. (1997). Regulation of mammalian acetyl-coenzyme A carboxylase. Annual Review of Nutrition, 17, 77-99.
18. Baumgartner, E., & Suormala, T. (1996). Multiple carboxylase deficiency: Inherited and acquired disorders of biotin metabolism. International Journal for Vitamin and Nutrition Research, 67(5), 377-384.
19. Albarracin, C. A., Fuqua, B. C., Evans, J. L., & Goldfine, I. D. (2008). Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 24(1), 41-51.
20. Spence, J. T., & Koudelka, A. (1984). Effects of biotin upon the intracellular level of cGMP and the activity of glucokinase in cultured rat hepatocytes. The Journal of Biological Chemistry, 259(10), 6393-6396.
21. Matschinsky, F. M. (2002). Regulation of pancreatic β-cell glucokinase from basics to therapeutics. Diabetes, 51(S1), S394-S404.
22. Bhuiyan, M. S., Shioda, N., & Fukunaga, K. (2008). Targeting protein kinase B/Akt signaling with vanadium compounds for cardioprotection. Expert Opinion on Therapeutic Targets, 12(10), 1217-1227.
23. Cohen, N., Halberstam, M., Shlimovich, P., Chang, C. J., Shamoon, H., & Rossetti, L. (1995). Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. The Journal of Clinical Investigation, 95(5), 2501-2509.
24. Halberstam, M., Cohen, N., Shlimovich, P., Rossetti, L., & Shamoon, H. (1996). Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes, 45(5), 659-666.